JCLA:BCR ABL1p210/p190融合基因转录本定量的方法的制定和评价

2019-01-18 MedSci MedSci原创

在BCR ABL1融合基因(FG)转录本检测中,标准发挥着重要作用。然而,实验室广泛使用的标准主要是基于质粒或cDNA,不能准确反映RNA提取和cDNA合成的过程。因此,本研究的目标是开发基于组装RNA的p210和p190 BCR ABL1FG转录本定量标准。 研究人员采用重叠聚合酶链反应(PCR)技术,首先将p210或p190 BCR ABL1FG转录本片段与4个对照基因(CGs;ABL1

BCR ABL1融合基因(FG)转录本检测中,标准发挥着重要作用。然而,实验室广泛使用的标准主要是基于质粒或cDNA,不能准确反映RNA提取和cDNA合成的过程。因此,本研究的目标是开发基于组装RNAp210p190 BCR ABL1FG转录本定量标准。

研究人员采用重叠聚合酶链反应(PCR)技术,首先将p210p190 BCR ABL1FG转录本片段与4个对照基因(CGs;ABL1, BCR, GUSB, B2M)生成p210FG CGp190FG CG。随后,利用组装RNA技术,制备p210FG CGp190FG CG组装RNA以及p210FG CGp190FG CG标准,其值由digital PCR (dPCR)指定。

结果显示,p210FG CGp190FG CG标准稳定均匀,与r2 > 0.98呈显著线性关系。在全国52个实验室进行的田间试验表明,p210样品中BCR ABL1值变异系数(CV%)58.6%,为129.6%p190样品中变异系数(CV%)73.2%,为194.0%。相比之下,p210p190样品在使用p210FG CGp190FG CG标准时,BCR ABL1CV%分别下降到35.6% 124.9%36.6% 170.6%。另外,在p210p190样品中,33.3%(3/9)CV%<50.0%,而在p210FG CGp190FG CG标准中,44.4%(4/9)77.8%(7/9)CV%值较低。

研究结果表明,使用p210FG CGp190FG CG标准,尤其是p190FG CG标准,显著降低检测BCR ABL1转录本的总变化率。

原始出处:

Yu Fu, Rui Zhang, Qisheng Wu, Development and evaluation of armored RNAbased standards for quantification of BCRABL1p210/p190 fusion gene transcripts

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747339, encodeId=2a601e4733943, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Nov 25 14:36:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813639, encodeId=3fa918136397d, content=<a href='/topic/show?id=0b289336250' target=_blank style='color:#2F92EE;'>#转录本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93362, encryptionId=0b289336250, topicName=转录本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 31 18:36:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786028, encodeId=9ff71e860286b, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 20 13:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444487, encodeId=9792144448e26, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525492, encodeId=eccc152549229, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542630, encodeId=64e5154263056, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-11-25 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747339, encodeId=2a601e4733943, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Nov 25 14:36:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813639, encodeId=3fa918136397d, content=<a href='/topic/show?id=0b289336250' target=_blank style='color:#2F92EE;'>#转录本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93362, encryptionId=0b289336250, topicName=转录本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 31 18:36:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786028, encodeId=9ff71e860286b, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 20 13:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444487, encodeId=9792144448e26, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525492, encodeId=eccc152549229, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542630, encodeId=64e5154263056, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747339, encodeId=2a601e4733943, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Nov 25 14:36:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813639, encodeId=3fa918136397d, content=<a href='/topic/show?id=0b289336250' target=_blank style='color:#2F92EE;'>#转录本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93362, encryptionId=0b289336250, topicName=转录本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 31 18:36:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786028, encodeId=9ff71e860286b, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 20 13:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444487, encodeId=9792144448e26, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525492, encodeId=eccc152549229, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542630, encodeId=64e5154263056, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-02-20 tulenzi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747339, encodeId=2a601e4733943, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Nov 25 14:36:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813639, encodeId=3fa918136397d, content=<a href='/topic/show?id=0b289336250' target=_blank style='color:#2F92EE;'>#转录本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93362, encryptionId=0b289336250, topicName=转录本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 31 18:36:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786028, encodeId=9ff71e860286b, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 20 13:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444487, encodeId=9792144448e26, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525492, encodeId=eccc152549229, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542630, encodeId=64e5154263056, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-01-20 huagfeg
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747339, encodeId=2a601e4733943, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Nov 25 14:36:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813639, encodeId=3fa918136397d, content=<a href='/topic/show?id=0b289336250' target=_blank style='color:#2F92EE;'>#转录本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93362, encryptionId=0b289336250, topicName=转录本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 31 18:36:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786028, encodeId=9ff71e860286b, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 20 13:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444487, encodeId=9792144448e26, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525492, encodeId=eccc152549229, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542630, encodeId=64e5154263056, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-01-20 licz0427
  6. [GetPortalCommentsPageByObjectIdResponse(id=1747339, encodeId=2a601e4733943, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Nov 25 14:36:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813639, encodeId=3fa918136397d, content=<a href='/topic/show?id=0b289336250' target=_blank style='color:#2F92EE;'>#转录本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93362, encryptionId=0b289336250, topicName=转录本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 31 18:36:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786028, encodeId=9ff71e860286b, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 20 13:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444487, encodeId=9792144448e26, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525492, encodeId=eccc152549229, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542630, encodeId=64e5154263056, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Sun Jan 20 04:36:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]

相关资讯

ARCH PATHOL LAB MED:短期快速冷冻乳房切除标本不会干扰乳腺癌生物标志物和分子检测

对乳腺癌标本进行彻底的大体检查需要非常薄对组织切片,这在大型乳房切除术样本中通常很难实现。本研究在福尔马林固定前实施了快速冷冻乳房切除术标本,以评估快速冷却乳房组织对随后的生物标志物和分子检测的影响。 研究人员将乳房切除术标本在-80℃下冷却20分钟,以促进组织以4mm间隔均匀切片增强小病灶的适当固定和鉴定。对用于辅助和分子测试的冷冻组织的完整性进行评估。研究人员对在外部机构确定了在活检中被

JCLA:迈瑞(mindray)抗丙肝病毒检测方法检测丙型肝炎病毒感染的效果评价

目前,丙型肝炎病毒(HCV)抗体检测用于丙型肝炎病毒感染筛查。在中国,最近启动了基于第三代免疫测定法的迈瑞抗丙肝病毒试验。本研究的目的是评价其与其他两种广泛使用的化验的诊断性能。 研究人员采用6个丙肝病毒感染血清转化板评价该方法的早期检测敏感性。采用迈瑞抗HCV、伊莱西抗HCV II和Architect抗HCV试验检测共1952个临床样本。使用至少一种抗丙肝病毒试验得到反应结果的样本,用重组

Anal. Chem:微生物所在微滴数字PCR技术研制方面取得进展

数字PCR是一种用于绝对核酸定量检测方法,具有前所未有的准确度和精确度,是继实时荧光定量PCR技术之后的第三代核酸定量扩增检测技术,在液体活检、肿瘤伴随诊断、无创产前筛查、病原载量监测等方面具有重要应用前景,是科研和临床领域的平台级新技术。数字PCR市场主流产品主要为欧美跨国公司的高端仪器,在科研和临床的应用还比较初步。数字PCR的更广泛使用和临床应用,仍然存在几个主要挑战,包括降低成本,集成仪器

英国开展呼吸检测癌症技术临床试验,1500名志愿者将参加

英国癌症研究会最新发布的消息说,研究人员将就一种新开发的呼吸检测癌症技术开展临床试验,该技术如发展成熟,有望带来更简单、高效的癌症早期检测方法。这项临床试验由英国癌症研究会剑桥中心的研究人员领衔开展,所用的呼吸测试设备由英国生物技术公司Owlstone Medical研发。据该研究会介绍,在正常的新陈代谢过程中,细胞的生化反应会使人体呼出的气体中含有一类被称为挥发性有机化合物的分子。如果人体患癌症

ARCH PATHOL LAB MED:通过磁共振成像检测到的前列腺癌-靶向活组织检查具有较高的Gleason模式4组分百分比,并且在根治性前列腺切除术中不太可

在格里森评分(GS)7前列腺癌中,格里森模式4(GP4)的数量是一个重要的预后因素,并影响治疗决策。而磁共振成像(MRI)靶向活检已越来越多地用于临床实践。本项目旨在研究MRI靶向活检是否可以检测出更高GP 4量的GS 7前列腺癌,以及是否改善活检/根治性前列腺切除术GS一致性。 研究人员共对243名癌症患者进行了成对标准和MRI靶向活检,其中65名患者接受了根治性前列腺切除术。活检结果包括

多国科研人员探索人体生物钟检测新法

有人是“早起鸟”,有人则是“夜猫子”,每个人都有自己一套独特的生物钟。目前,多国科研人员正尝试开发快速检测人体生物钟的新法,以期更好地了解人体,保障健康。